Michael Christel

A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential future impacts for gene therapy regulation and market access.

With today's pharmacy landscape shaken by unprecedented and wider disruption to healthcare support and delivery, community and independent entities strive to remain an integral cog in the mix.

In this Pharmaceutical Commerce video interview, Joerg Tritschler, a partner in Simon-Kucher’s life sciences division, explores the two major strategies big pharma companies are employing amid current macro challenges and efforts to offset looming patent losses to blockbuster brands.

In this Pharmaceutical Commerce video interview, Joerg Tritschler, a partner in Simon-Kucher’s life sciences division, discusses the hottest therapeutic settings for dealmaking activity at the moment—and one platform approach in particular poised to be at the center of future M&A and licensing pursuits.

In this Pharmaceutical Commerce video interview, Joerg Tritschler, a partner in Simon-Kucher’s life sciences division, discusses the important and often missing element in strategic planning for clinical-stage companies—and ways to close that focus gap.

In this Pharmaceutical Commerce video interview, Joerg Tritschler, a partner in Simon-Kucher’s life sciences division, talks about the challenging environment today for emerging biopharma companies in demonstrating the value of their promising early-stage drug candidates to potential investors or buyers.

In this Pharmaceutical Commerce video interview, Joerg Tritschler, a partner in Simon-Kucher’s life sciences division, discusses the positive signs from rising activity levels in biopharma M&A— and what the momentum may mean for industry dealmaking and partnership efforts in the months ahead.

A deep dive into the complex playing field for M&A and partnering pursuits in today’s increasingly make-or-break landscape for biopharma innovation.

Q&A explores new opportunities to strengthen supply chain resilience—and build on the lessons learned.

Startup pioneers the longitudinal health record

Introducing our first deep dive into pharma's indispensable partner—the 3PL

A conversation with Michael Abrams, co-founder and managing partner, Numerof & Associates

How FDA’s new guidance on real-world data reshapes critical “fit-for-purpose” evaluations

Administrator on how pandemic has affected milestone events—the so-called “biodollars”—in life sciences’ deal structures

Software company on mission to infuse efficiency into the pharmacy benefits system

Capital infusion, Nasdaq debut ignite ‘agile’ approach to attracting patients without bounds

A digital health company’s quest to improve the delivery and scaling of lab testing

The promise of advanced AI in transforming the value picture in drug development

A conversation with Justin Hoss, technology leader for life sciences, KPMG

Healthcare Distribution Alliance CEO talks Covid lessons from onset until now—and how this key pharma link is faring in the current supply chain crisis

One pharma’s IVF education and access mission

Delivering critical insights and relevant messaging at precise moments of the patient journey

The pandemic has accelerated the adoption of enterprise resource planning in pharma supply chain management, as the recent US rise of one “technology enabler” attests

Is it the next wave of communication for sales and marketing teams?

Hurricane Ida reminds us of the importance of an effective supply chain

A conversation with Volker Kirchner, director, temperature control solutions, World Courier

The quest to standardize RFID tagging across the pharma supply chain

Market intelligence analyst discusses new trends and emerging strategies in pharma revenue management, given today’s fast-evolving technological and regulatory dynamics

Roche repeats at No. 1 position; AbbVie vaults five spots

C-suite executive shares knowledge surrounding data security and risk mitigation